The data is big,please wait a moment......
| EWAS ID | GO ID | Class | Disease/Phenotype [sample size n] |
Sample groups (case/control, trait, cell type etc.) |
Categories | GO Term Name | GO Term Gene Number | Gene Number Annotated In The GO Term | Pvalue | |
| Group1 [sample size n] |
Group2 [sample size n] |
|||||||||
| EWAS1296 | GO:0060537 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | muscle tissue development | 175 | 143 | 0.000019 |
| EWAS1296 | GO:0060548 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | negative regulation of cell death | 439 | 337 | 0.000028 |
| EWAS1296 | GO:0060589 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
molecular_function | nucleoside-triphosphatase regulator activity | 443 | 357 | 0.000000 |
| EWAS1296 | GO:0060612 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | adipose tissue development | 11 | 11 | 0.000000 |
| EWAS1296 | GO:0060627 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | regulation of vesicle-mediated transport | 132 | 115 | 0.000000 |
| EWAS1296 | GO:0061024 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | membrane organization | 471 | 376 | 0.000000 |
| EWAS1296 | GO:0061061 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | muscle structure development | 300 | 247 | 0.000000 |
| EWAS1296 | GO:0061082 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | myeloid leukocyte cytokine production | 11 | 11 | 0.000000 |
| EWAS1296 | GO:0061134 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
molecular_function | peptidase regulator activity | 174 | 141 | 0.000051 |
| EWAS1296 | GO:0065007 | disease | multiple sclerosis [n=96] |
multiple sclerosis patients treated with fumaric acid esters(FAE) [n=42] |
untreated/treatment naive multiple sclerosis patients(Naive) [n=54] |
biological_process | biological regulation | 6926 | 5104 | 0.000000 |